Agoracom Blog Home

Posts Tagged ‘tsx-v’

#Coronavirus Scare Gives #Telehealth an Opening to Redefine Healthcare #Mhealth SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 6:12 PM on Thursday, March 12th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Coronavirus Scare Gives Telehealth an Opening to Redefine Healthcare

With the coronavirus threatening to become a pandemic, health systems and telehealth vendors see this as an opportunity to bring connected health to the forefront – and reshape the future of healthcare.

By Eric Wicklund

March 05, 2020 – As Congress votes on a funding package that includes Medicare waivers for some telehealth services and the Health Information and Management Systems Society (HIMSS) cancels its conference in Florida, healthcare providers across the country are looking at how connected care programs can be used to handle the coronavirus – also called COVID-19 – threat.

Most see the exercise as an extension of their preparations for flu season. Some see this as an opportunity to lobby for telehealth adoption across the board, saying a possible epidemic offers ample evidence of the value of telehealth and mHealth.

Defining Telehealth’s Value in a Changing Landscape

“COVID-19 is different because we do not know all the factors surrounding transmission and its effects on patients,” Jason Hallock, Chief Medical Officer for SOC Telemed, points out. â€œBecause coronavirus is new and there have been a significant number of deaths, the uncertainty surrounding that is scaring both patients and the general public. Our healthcare workers do not have all the answers yet. Telehealth providers are challenged to make recommendations when there are still many unknowns. Telemedicine can be useful to evaluate and reassure patients in alternative settings, and also can be used to help patients decide who needs to be seen in the hospital or an alternative setting like an urgent care.”

Hallock says telehealth can help by enabling healthcare providers to treat isolated patients, thus preventing the spread of what has so far been an extremely contagious virus.

In a Q&A with mHealthIntelligence, Peter Antall, MD, President and Chief Medical Officer for American Well, offered an in-depth take on how telehealth might be used.

READ MORE: Scripps Researchers Use mHealth Wearables to Track Flu Outbreaks

Q. Telehealth has long been seen as an ideal means of expediting care during flu outbreaks. How is the coronavirus scare different? Does this pose any unique challenges that telehealth can address?

A. The novel coronavirus, or COVID-19, is similar to influenza in how it is transmitted (airborne), how symptoms manifest themselves, and the fear it stirs among those individuals at risk. When evaluating patients through telehealth, we use similar methodology as that used for influenza, except that the current Centers for Disease Control and Prevention (CDC) recommendations call for risk stratification based on known exposure or travel to endemic areas and referral for testing for those at high risk or those who are sick enough to need hospital care. Also, unlike with influenza, there are no current specific treatments, like antivirals, for the coronavirus at this time. 

If local person-to-person spread expands to wide community spread, we expect care will need to evolve to a method that is quite similar to how we treat influenza today. Under those circumstances, we will likely begin diagnosing coronavirus-like illness (CLI) on a clinical basis, without testing. We would likely then only be expected to refer inpatients with CLI who need hospital care clinically, while those with milder symptoms will likely be treated and monitored at home so as to limit the spread of this disease and not overwhelm our healthcare facilities.

In this way, telehealth is an ideal venue for an outbreak like this. We can increase access to care. We can offer care that is commensurate with the acuity and nature of the symptoms and make referrals as needed. This helps with infection prevention and control and also allows patients to receive their care in the home without exposing themselves to further illness.

One other notable point is the potential for telehealth to help in providing routine care for other conditions and offset coronavirus fears in the . Patients have other healthcare needs unrelated to coronavirus, but many are afraid to go to healthcare settings for fear of catching disease. This has begun to result in a migration of patients to telehealth. For example, on February 25, we saw telehealth urgent care patient volume that was 11 percent higher than expected. Many patients are now sharing anecdotes indicating they were afraid to sit in a waiting room, so they used telehealth instead.

READ MORE: Using Telehealth Technology for Care Coordination During a Disaster

Q. Are there new tools or technologies available that can be useful in dealing with the coronavirus?

A. Telehealth itself is a tool in this fight. Keep in mind that there are many varieties of telehealth. It can be used to connect a doctor or other provider with a patient in the home via smartphones or tablets. It can also be used for provider (specialist)-to-provider consultations in remote areas, for example. Telehealth carts also exist in healthcare settings and can be used not only to import care, but also to limit healthcare workers’ exposure to the virus by using a cart in the isolation room.  We see patients primarily through live video interactions, but we also can fall back to informed telephone calls, synchronous chatting for therapy and asynchronous secure messaging for ongoing communications.

The use of symptom trackers and chatbots is another promising area for coronavirus response. These technologies allow algorithms to be created and adjusted as more is learned about the coronavirus. These bots interact with patients and can perform assessments, triage and ongoing support. The bots can even escalate an interaction to a telehealth encounter or refer the patient for in-person care.

Finally, home monitoring and medical tricorders are another promising approach to care. Traditional remote patient monitoring has established value for managing certain chronic conditions, but the next wave of home monitoring includes consumer devices like smartwatches (like the Apple Heart Study), home TVs, and home medical tricorders like Tytocare that can perform a remote examination. These tools aid clinicians and patients and provide more robust health data conveniently from the home setting. Providers can also use the data generated to better care for the patient or regularly monitor certain conditions.

Q. What must care providers know about telehealth before using it to deal with the coronavirus?

READ MORE: HHS Is Looking For mHealth Devices That Can Diagnose Influenza

A. Providers must know and understand their role in this or any other healthcare crisis. They should be well informed and trained to follow current CDC or World Health Organization guidelines. They should also understand that telehealth is a powerful tool for helping fight this outbreak. And they should know that telehealth is a safe way to treat and/or triage these patients. Whether the provider is a primary telehealth provider or is not using telehealth today, there is a real opportunity to participate and play a role in the response. 

Providers who have a brick-and-mortar practice should be encouraged to use telehealth as a triage tool. Providers also need to understand that during this time, patients with other non-respiratory conditions also need care. These patients should be afforded a safe way to access care without risk of infection. Telehealth is also a tool to aid in this process, as some patients are fearful of going to healthcare facilities right now. The office-based provider can likewise process other patients by practicing this way.

Q. What are the barriers or challenges associated with using telehealth to deal with the coronavirus scare?

A. Telehealth visits are typically sufficient to complete a robust initial assessment. This allow the provider to assign a risk category, make other diagnoses, or deem the patient as “worried well.” Some patients may require additional care, as most telehealth in the home lacks certain medical peripherals that might be needed. Other reasons for referral would include a high-risk patient who needs to be tested or a patient who requires escalation of care due to the severity of their illness. Telehealth visits are generally sufficient for screening patients, assigning a risk category, answering questions and recommending the next steps a patient should take.

The barriers to telehealth—such as instances when the patient and provider do not yet have a relationship—are easily overcome providers receive similar training around the use of telehealth and as longitudinal patient records become more available to guide care. Occasionally the lack of medical peripherals or the inability to touch the patient during an exam is a barrier, as some patients need hands on care (e.g., IV, procedures). We have policies that mitigate these problems in most cases. However, on occasion, a telehealth patient must be referred for in-person evaluation.

Q. Is there anything that the CDC or any other government agency can do to support telehealth adoption to deal with the coronavirus? 

A. It is useful for the CDC (and the WHO) to highlight the important role of telehealth in this outbreak because it certifies our role within the broader medical community and raises awareness about this tool.

It would be helpful if the CDC were to make specific recommendations to telehealth providers that relate to telehealth evaluation of the coronavirus and associated referrals, coding and monitoring. It would also be helpful if the CDC were to play a role in advocacy efforts focused on government reimbursement, particularly in this emergency situation. Efforts to increase consumer awareness about telehealth as a safe option for care also could prove essential. When this outbreak settles down, we would encourage the CDC and HHS to collaborate around coronavirus standards of care and preparedness so that patients can expect telehealth providers to be ideally prepared and well-coordinated for the next outbreak and so that we can offer high-quality care in this manner to all Americans.

We also believe that our public health system would benefit greatly from owning its own telehealth network infrastructure. This would allow the CDC to better scale up, solve for geography and improve surveillance. It would even allow its public health workers to use technology to monitor patients under quarantine in the home, saving themselves travel and limiting healthcare workers’ exposure.

Q.  What more can be done with telehealth in the future to plan for these types of outbreaks, or to perhaps address them before they become serious?

A. Much needs to be done throughout our country to better prepare. We need permanent leaders placed at the U.S. Department of Health and Human Services, the National Institutes for Health, the US Department of Homeland Security and other key areas, and we need to reinstate a pandemic-preparedness role at the National Security Council. We need to fund international efforts to improve screening and research for emerging diseases, and we need surveillance programs and good international coordination. We need to fund (not decrease funding) for our frontline groups, like the CDC, HHS and local public health services. These are our fighters, and we need them ready and funded properly as an outbreak like this is a national security issue. We need stockpiles of materials. Finally, we should be partnering with the pharmaceutical industry on affordable medications and vaccine research.

Our national telehealth operation today acts like an emergency alert system. We see cases or potential cases before they are reported. At American Well, our influenza activity indicator map is more accurate and more timely than that of the CDC. We already play a meaningful role in many disease states, including outbreaks. There are still many adoption and awareness challenges that exist when it comes to telehealth. Hopefully this unfortunate event will help consumers, providers and others start to more clearly see how they can and should use telehealth for future healthcare needs.

Another barrier that we continue to work on is that of reimbursement. Telehealth is a cost-effective way of receiving care, but it is still not always a covered benefit by insurance. Most commercial plans are reimbursing and there is increasing adoption in Medicare Advantage and Medicaid managed care. But there are still gaps, including a big gap in fee-for-service coverage for Medicare coverage in the home. Efforts at reform are underway (see the CONNECT Act), but more work needs to be done so that all Americans can take advantage of this amazing service.

Additionally, with coordination being so important during outbreaks like this, the simple step of integrating telehealth with other health information systems, such as EHRs or clinical-decision support, can make care more seamless and foster better care coordination. This would speed up access to critical care. Case in point: Consider a scenario where a patient consults with a physician over a telehealth network and displays symptoms of COVID-19 while presenting one or more correlating risk factors. The physician could easily document the experience, dispatch an alert to a local ED, and ensure precautions are taken by medical staff to usher this patient into a contained room or unit to begin testing and treatment. We’re working to ensure this type of communication is happening at all levels, but there’s still much room for improvement on this front. 

Health System Execs Respond to the Threat

In an op-ed prepared for the Alliance for Connected Care, Todd J. Vento, MD, MPH, Intermountain Healthcare’s Medical Director of Infectious Diseases Telehealth Service; Ethan Booker, MD, Medical Director of MedStar’s Telehealth Innovation Center; and Lawrence “Rusty” Hofmann, MD, Stanford Health’s Medical Director of Digital Health, made their pitch for telehealth:

“Telehealth, which has proven to be a very useful tool in addressing patient needs during flu season, will improve our collective ability to address COVID-19 if it hits on a larger scale. Telehealth offers several advantages over in-person care in the event of a pandemic.

One key advantage of telehealth is speed,” the three wrote. “Patients can access clinicians 24/7 without an appointment or physical trip to the doctor. Using telehealth, our providers in the Stanford Primary Care team, MedStar Health and Intermountain Healthcare have been actively evaluating and treating patients with influenza.  Current providers at Stanford Health estimate that almost 50% of patients are getting oseltamivir (Tamiflu).  Because there is no current, specific medication for Coronavirus, we must be able to advise patients of reasonable self-directed treatment and surveillance to keep them home. 

Keeping patients at home is a significant advantage of telehealth. In-home video visits limit community exposure by allowing patients to avoid contact with other patients in waiting rooms and direct contact with providers during the exam.  Our health systems have providers who are equipped to work from their own homes, significantly increasing the safety of providers and bolstering the workforce to respond to crisis.  Workforce readiness in a crisis that may include such dramatic measures as school and day care closures is a significant concern for health systems which may be strained to respond.  Health systems are also using telehealth to continue surveillance of patients already identified as at risk while keeping them at home.

Next, telehealth ensures that treatment in brick-and-mortar settings is reserved for high-need patients.  Moreover, with patients being seen in their own homes, providers and health systems will be able to triage and screen exponentially more patients with telehealth vs. an in-person visit.

Finally, telehealth allows patients who do not have access to infectious diseases (ID) specialists to access this specialized care from the small number of experts across the country. When Intermountain first offered ID telehealth consultation to rural systems throughout the west, one provider fielded 1,000 consultation requests in the first fifteen months. To date, the service has provided telehealth care to over 4,700 patients, 50 percent of whom are over 65 years old.

Each of these advantages illustrate how telehealth can thwart the spread of COVID-19 and stop it from overwhelming our already stretched medical system.”

The three health executive also urged lawmakers to take action to reduce barriers to telehealth that have kept adoption low:

“Congress must act to ensure that seniors – a particularly vulnerable population generally and for this virus in particular – are able to receive necessary triage and care through telehealth. 

Today, there are restrictions in Medicare that prevent providers outside of very rural areas from being paid for care provided through telehealth. As a result, many providers do not offer telehealth services to seniors. The lack of reimbursement creates a perverse incentive of encouraging patients to come for in-person care, which will only overwhelm our health system as well as augment the virus’s spread.

Congress must give the Secretary of Health and Human Services the ability to waive these restrictions in times of public health emergencies. As part of the bipartisan, bicameral CONNECT for Health Act, telehealth champions in Congress foresaw this need and drafted a provision that would give the Secretary the ability to waive telehealth restrictions just as he/she would waive Conditions of Participation, Stark Laws licensure, or other requirements when public health emergencies are declared.”

Source: https://mhealthintelligence.com/news/coronavirus-scare-gives-telehealth-an-opening-to-redefine-healthcare

Democracy Labs uses Datametrex AI $DM.ca #Nexalogy Tech to Study #Coronavirus Misinformation

Posted by AGORACOM-JC at 7:35 AM on Thursday, March 12th, 2020
  • Announce that Democracy Labs successfully used Nexalogy’s technology to monitor #covid19 and #coronavirus to identify misinformation campaigns and Fake News
  • Democracy Labs is a US based organization providing a hub for ongoing technology and creative innovation that serves progressive campaigns and organizations at the national, state, and local levels.

TORONTO, March 12, 2020 — Datametrex AI Limited (the “Company” or Datametrex”) (TSXV: DM) (FSE: D4G) is pleased to announce that Democracy Labs successfully used Nexalogy’s technology to monitor #covid19 and #coronavirus to identify misinformation campaigns and Fake News. Democracy Labs is a US based organization providing a hub for ongoing technology and creative innovation that serves progressive campaigns and organizations at the national, state, and local levels. In addition to misinformation about Covid-19 DemLabs has also used Nexalogy tech to examine Islamophobia against U.S. Representative Rashida Tlaib.

Key takeaways:

  • 450,000 tweets analyzed from March 1st through 4th using hashtag #covid19
  • Russia Today suggested that the U.S.A. primaries be cancelled and was promoted by BOTS

Results of these campaigns can be found by clicking the attached links:

https://insights.nexalogy.com/democracy-labs-uses-nexalogy-tech-to-study-coronavirus-misinformation-b88ea13c4bed
https://nexalogy.com/insights/keep-an-eye-on-trolls-activity-and-report-harassment-to-twitter/

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

For further information, please contact:

Jeff Stevens
Email: [email protected]Phone: 647-777-7974

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

INTERVIEW: Datametrex $DM.ca – The Small Cap #A.I. Company Governments Use To Fight Fake News & Election Meddling

Posted by AGORACOM-JC at 5:01 PM on Wednesday, March 11th, 2020

Until now, investor participation in Artificial Intelligence has been the domain of mega companies and those funded by Silicon Valley.  Small cap investors can finally consider participating in the great future of A.I. through Datametrex AI (DM: TSXV) (Soon To Be Nexaology) who has achieved the following over the past few months:

  • Q3 Revenues Of $1.6 million,  an increase of 186%
  • 9 Month Revenues Of $2.56M an increase of 37%
  • Repeat Contracts Of $1M and $600,000 With Korean Giant LOTTE   
  • $954,000 Contract With Canadian Department of Defence To Fight Social Media Election Meddling
  • Participation In NATO Research Task Group On Social Media Threat Detection 

When a small cap Artificial Intelligence company is successfully deploying its technology with military and conglomerates, smart investors have to take a closer look.   That look can begin with our latest interview of Datametrex CEO, Marshall Gunter, who talks to us about the use of the Company’s Artificial Intelligence to discover and eliminate US Presidential election meddling.  The fake news isn’t just targeting candidates specifically, it also targets wedge issues such as abortion cases now before the US Supreme Court and even the Coronavirus.   Watch this interview on one of your favourite screens or hit play and listen to the audio as you drive. 

NORTHBUD $NBUD.ca – Legal #pot industry more than doubles contribution to Canada’s #GDP since #legalization: StatsCan $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 4:32 PM on Monday, March 9th, 2020

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

Legal pot industry more than doubles contribution to Canada’s GDP since legalization: StatsCan

  • Canada’s cannabis industry represented $7.24 billion to the country’s gross domestic product in December
  • Illicit cannabis market’s contribution to Canada’s GDP has fallen by over 20 per cent

The country’s legal cannabis market represents $3.0 billion of economic output to Canada’s GDP, an increase of 138 per cent when recreational pot was legalized in Oct. 2018. Meanwhile, the illicit cannabis market’s contribution to Canada’s GDP has fallen by over 20 per cent to about $4.18 billion in that same time.

Source: https://www.bnnbloomberg.ca/cannabis-canada-pot-industry-added-nearly-7-24b-to-gdp-in-august-statscan-says-1.1397728

#Palladium, #rhodium demand to remain, despite #virus outbreak SPONSOR: New Age Metals $NAM.ca $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN

Posted by AGORACOM-JC at 5:40 PM on Thursday, March 5th, 2020

SPONSOR: New Age Metals Inc. The company owns one of North America’s largest primary platinum group metals deposit in Sudbury, Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces Inferred. Learn More.

Palladium, rhodium demand to remain, despite virus outbreak: analyst

  • Though the coronavirus outbreak may affect near-term automobile demand, long-term demand for palladium and rhodium will remain unchanged

By: Nick Jonson

Washington — Though the coronavirus outbreak may affect near-term automobile demand, long-term demand for palladium and rhodium will remain unchanged unless automakers substitute for other metals, managing director Frederic Panizzutti of MKS Dubai said.

“If I was a carmaker, I would definitely stock palladium while the price is lower, and I believe this is going to keep palladium strong, even if the demand goes down in China, the UK, or the demand for parts decreases,” Panizzutti said in an interview this week.

Rhodium and palladium, along with platinum, are used in automobile catalytic converters to control emissions of certain greenhouse gases and pollutants.

“It’s a bargain for car manufacturers to be able to acquire palladium if it goes lower; it’s been a one-way street for months now,” Panizzutti said, referring to the recent rallies in palladium and rhodium.

NYMEX palladium has risen nearly 25% since the start of the year to reach an intraday high of $2,789.80/oz on February 27. NYMEX palladium for June delivery closed at $2,469.40/oz on Thursday.

Rhodium, which is not traded on major exchanges, has risen nearly 114% since the start of the year. The Platts New York Dealer rhodium price was assessed at $12,700-$13,000/oz on February 27.

Analysts have attributed the sharp price increase to automakers trying to secure enough metal for catalytic converters that meet new emissions standards in China, India and Europe, as well as the US and UK.

Further spread of the coronavirus outbreak globally could reduce automobile demand, along with the projected 1 million oz supply deficit in palladium, Panizzutti said.

The China Passenger Car Association on Wednesday said new car sales in China had plummeted 80% in February from a year ago, the biggest monthly decline on record, though it declined to provide a figure.

Analysts attributed the declining sales to government restrictions to limit the spread of the coronavirus in China, where it began in Hubei Province. Hubei is a major auto manufacturing hub in China.

But even if the coronavirus outbreak becomes a global pandemic, governments and businesses will have to adapt as they do nearly every year with widespread influenza outbreaks, Panizzutti said.

Automobile production, and by extension palladium and rhodium demand, would continue, though possibly at a lower rate, he added.

PLATINUM SUBSTITUTION

“I believe the palladium price now is far over the threshold that automakers are willing to accept,” Panizzutti said.

But substituting platinum for palladium in catalytic converters takes time due to design and testing procedures, he noted.

“In my opinion, it should happen, whether it takes several months or longer because the palladium situation is unsustainable. And I see no reason why the situation should change if nothing changes in the supply/demand balance,” Panizzutti said.

“And the only way to change the supply/demand balance is to switch partially or totally from palladium to platinum. If there is no switch, the situation will be the same and will remain a struggle for manufacturers to get hold of material,” he said.

Source: https://www.spglobal.com/platts/en/market-insights/latest-news/metals/030520-palladium-rhodium-demand-to-remain-despite-virus-outbreak-analyst

First Look at the Nine CBD Consumer Archetypes in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 3:47 PM on Thursday, March 5th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Click Here for More Info

Mota large
  • New Frontier Data’s second consumer report in its EU CBD series provides a comprehensive overview of the European CBD consumer experience

New Frontier Data, the global authority in data, analytics and business intelligence on the cannabis industry, publishes the second volume of its EU CBD Consumer Report Series: Segmentation & Archetypes, in partnership with Deep Nature Project and Mile High Labs. Drawing from the groundbreaking surveying of over 3,000 European CBD consumers across 17 European nations, this study results in the most comprehensive consumer archetype report for European CBD consumers to date.

“Europe’s booming consumer interest in CBD and CBD-infused products across the Food & Beverage and Health & Beauty sectors continues to create material B2B and B2C market opportunities. Data-driven insights of both EU and North American CBD consumerism, drawing from not only comparative analysis but also known geo-centric market dynamics and drivers, helps us educate and guide brands on how to address CBD consumer priorities while managing known or expected challenges in this new CBD space,” said New Frontier Data Founder & CEO Giadha Aguirre de Carcer. “This report fills a major gap in business intelligence in the CBD industry not only in Europe, but worldwide, providing new and existing cannabis or hemp industry stakeholders with a uniquely valuable and timely resource.”

Key findings from the report include:

  • 4 of the 5 consumer archetypes have purchased CBD; the Ambivalent & Experimental Consumers instead source CBD from family and friends
  • The largest consumer archetype, the Integrative & Consistent Consumers, are frequent users and staunch believers in CBD’s medical efficacy
  • 26% of Europeans aged 18-34 have tried CBD, compared to 16% of the general population
  • 73% of self-reported consumers claimed CBD has positively affected their quality of life
  • A third (34%) of non-consumers are somewhat or very curious about trying CBD
  • 49% of CBD purchasers who did not themselves consume indicated buying it for a family member
  • Male consumers report spending more on CBD products than female consumers, with more than a third of men (35%) reporting spending €100 or more per month
  • 72% of consumers and 17% of non-consumers considered themselves likely to purchase CBD in the next 6 months
  • Consumers who use CBD primarily for medical reasons were the most frequent CBD consumers, with nearly half (45%) consuming it at least daily

The EU CBD Consumer Report Series: Segmentation & Archetypes is available for FREE Download at: https://newfrontierdata.com/product/the-eu-cbd-consumer-report-2020-segmentation-and-archetypes/

About New Frontier Data:

New Frontier Data is an independent, technology-driven analytics company specializing in the global cannabis industry. It offers vetted data, actionable business intelligence and risk management solutions for investors, operators, researchers and policy makers. New Frontier Data’s reports and data have been cited in over 80 countries around the world to inform industry leaders. Founded in 2014, New Frontier Data is headquartered in Washington, D.C., with additional offices in Denver, CO and London, UK.

New Frontier Data does not take a position on the merits of cannabis legalization. Rather, its mission and mandate are to inform cannabis-related policy and business decisions through rigorous, issue-neutral and comprehensive analysis of the legal cannabis industry worldwide. For more information about New Frontier Data, please visit: https://www.NewFrontierData.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005341/en/

CLIENT FEATURE: CardioComm Solutions $EKG.ca – Putting Your Heartbeat Into The Cloud For Instant Diagnostics $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 6:03 PM on Monday, March 2nd, 2020

Global Leaders in Mobile  ECG Connectivity

  • 20 years of medical credibility licensing technologies to hospitals, physicians, remote patient monitoring  platforms, research groups and commercial call centers
  • Sold into > 20 countries, with the largest customer base located in the US
  • Class II medical device clearances and device agnostic for collecting, viewing, recording, analyzing and  storing of ECGs for management of patient and consumer health
  • ECG solutions for both consumer (OTC) and medical (Rx) markets
  • Owns all IP and source code
  • Market expert contributor for reports in m‐health, mobile cardiac monitoring and new advances in  consumer health and wellness monitoring

Recent Highlights

Physician Groups Order The Heartcheck(TM) Cardibeat For In-Home Arrhythmia And Atrial Fibrillation Monitoring

  • Confirms market traction with orders being placed by physician groups for the newly launched HeartCheck™ CardiBeat Handheld ECG monitor and GEMS™ Mobile Smartphone app for prescribed in-home arrhythmia monitoring.
  • Partners in Advanced Cardiac Evaluation, the largest arrhythmia practice in Ontario (Canada) placed a first order of the HeartCheck™ CardiBeat Handheld ECG monitors and is recommending its patients to use the devices for one year of in-home, self-monitoring with an emphasis on detecting a recurrence of Atrial Fibrillation following cardiac ablation treatment for AF.

Industry News

Company Accolades

FULL DISCLOSURE: CardioComm Solutions Inc. is an advertising client of AGORA Internet Relations Corp.

PyroGenesis $PYR.ca Announces New Website Launch $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 3:29 PM on Thursday, February 27th, 2020
  • Announced the launch of its redesigned website taking effect this March
  • Website has been revamped to include new features and improved functionality that provide instant access to essential information and features geared towards PyroGenesis’ interested parties 

MONTREAL, Feb. 27, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is proud to announce the launch of its redesigned website taking effect this March. The website has been revamped to include new features and improved functionality that provide instant access to essential information and features geared towards PyroGenesis’ interested parties.  

PyroGenesis’ new website will be continuously updated with business developments, events, company presentations, media mentions and press releases. Once launched, visitors are encouraged to explore the website and sign up for direct emails from the Company.

“We are happy to unveil our redesigned website which offers a clean and modern design providing a more comprehensive understanding of PyroGenesis’ technologies,” said Mr. P Peter Pascali, CEO and President of PyroGenesis. “We believe that this website will allow our visitors to have a very informative experience as we continue to grow and increase our market presence. I trust the timing of this news release is not lost on our readers.”

Of note, it is possible that, during this transition, PyroGenesis’ website may be under maintenance for a period up to 24 hours. It is also important to note that, during the weeks following the launch date, the redesigned website may be experiencing some minor technical adjustments. PyroGenesis’ team will work diligently to ensure all issues are resolved in a timely manner. The company looks forward to hearing your comments and feedback.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

For further information please contact:

Rodayna Kafal, Vice President Investors Relations and Strategic Business Development
Phone: (514) 937-0002, E-mail: [email protected] 

RELATED LINK: http://www.pyrogenesis.com/

REPEAT: Mota Ventures $MOTA.ca Signs Letter of Intent for Merger with Stillcanna $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM at 9:10 AM on Thursday, February 27th, 2020
http://www.smallcapepicenter.com/Mota%20Square%20Logo%20For%20Blog.jpg
  • Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts
  • Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe

VANCOUVER, BC / ACCESSWIRE / February 26, 2020 / Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF)(FRANKFURT:1WZGR) (“Mota“) and Stillcanna Inc. (STIL)(SCNNF)(A2PEWA) (“Stillcanna“) are pleased to announce that they have entered into a letter of intent (the “Letter of Intent“), dated effective February 25, 2020, pursuant to which Mota proposes to acquire all of the outstanding share capital of Stillcanna (the “Proposed Transaction“).

Strategic Merger

Mota is a globally-focused CBD product development and marketing company with established online retail brands in both the U.S. and Europe. Through its acquisition of First Class CBD, Mota has become a significant direct-to-consumer retail brand in the United States. In 2019, First Class CBD (then, a division of Unified Funding, LLC) realized approximately C$28.7 million in revenue with an EBITDA of approximately 12.5%.1 Mota’s successful e-commerce platform currently serves over 140,000 online customers and has generated over 400,000 leads in the United States. With the roll-out of First Class CBD’s proven e-marketing strategy throughout Europe, Mota believes that a merger with a high-quality CBD producer is of paramount importance in order to capture the large margins in the CBD-product supply chain.

Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts. Using proprietary extraction techniques and purpose-built equipment, Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe. Stillcanna’s Polish extraction facility, NEXUS, features industrial-scale centrifugal chromatography equipment that allows for the production of bulk THC-free CBD distillate as well as custom Cannabinoid profiles. In February 2020, Stillcanna’s Romanian extraction facility, ORIGIN, which operates pursuant to a joint venture between Stillcanna and Dragonfly Biosciences Ltd., received approval from the Ministry of Health and the Anti-Drug Agency to become the first government recognized extraction facility in the country. To date C$23,000,000 has been invested by Stillcanna in the cultivation and extraction operations, with current cash on hand in Stillcanna of approximately C$7,000,000.

Stillcanna’s CBD extracts are key to unlocking additional value in Mota’s retail offerings in Europe. Through Stillcanna, Mota hopes to guarantee the supply of high-quality CBD for its expanding product line in Europe, while the large production capacity of NEXUS and ORIGIN will allow Mota to be a key supplier of legal CBD products in Europe.

“We are very excited to pursue a transaction with Stillcanna. The merger of this large-scale, high-quality CBD producer will fit brilliantly with Mota’s strategic expansion plan to vertically integrate operations in Europe while increasing profit margins in product offerings. Product awareness and availability are still quite limited in Europe, which presents an opportunity for Mota to further establish its brands in a market that is expected to experience rapid growth in the near term. With the Stillcanna merger, we’re putting together a team that can create, market and sell consumer CBD products to European customers,” stated Ryan Hoggan, CEO of Mota.

“Combining a company that has established brands and direct-to-consumer sales channels with one that has proven CBD extraction expertise makes perfect sense to us,” commented Jason Dussault, CEO of Stillcanna. “The wholesale landscape for CBD has changed dramatically in the past year, and the creation of a seed-to-consumer CBD company in the growing European market creates a direct path to profitability. This merger completes the circle for Stillcanna, evolving from a seed to CBD concentrate company to a seed to retail sales company.”

Merger Details

Under the terms of the Proposed Transaction, Mota would acquire all of the outstanding share capital of Stillcanna by way of a statutory plan of arrangement under the Business Corporations Act of British Columbia Canada. Shareholders of Stillcanna (the “Stillcanna Shareholders“) would receive one common share of Mota for every 1.8 common shares of Stillcanna held at the time of exchange (the “Exchange Ratio“). Based on the current outstanding common share capital of Stillcanna, it is anticipated that Mota would issue approximately 61,597,082 Mota shares to complete the Proposed Transaction.

Upon completion of the Proposed Transaction: (i) all outstanding incentive stock options of Stillcanna will be exchanged for options to purchase Mota shares on the basis of the Exchange Ratio and will thereafter be subject to the incentive stock option plan of Mota; and (ii) all unexercised share purchase warrants of Stillcanna will be exchanged for warrants to purchase Mota shares on the basis of the Exchange Ratio and will expire in accordance with their current expiry dates.

Mota and Stillcanna are at arms-length. The Proposed Transaction does not constitute a reverse-takeover of Mota, nor is it expected to result in a change of control of Mota within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Upon completion of the Proposed Transaction, there will be no changes to the management or the board of directors of Mota and it is expected that members of management and the board of Stillcanna will continue to assist in relation to the management of Stillcanna’s business.

Completion of the Proposed Transaction remains subject to a number of conditions, including, but not limited to: (i) satisfactory completion of due diligence; (ii) negotiation of definitive, legally-binding documentation; (iii) receipt of any required regulatory approvals, including the court; (iv) the approval of the Stillcanna Shareholders; (v) receipt of a satisfactory fairness opinion in respect of the Proposed Transaction; (vi) Stillcanna having arranged to amend the terms of certain existing employment and consulting engagements; (vii) shareholders of Stillcanna holding at least 40,000,000 of the outstanding share capital of Stillcanna having agreed to the terms of a pooling arrangement restricting their ability to trade one-half of the Mota shares they receive for a period of six months following completion of the Proposed Transaction; (viii) Stillcanna having positive working capital of not less than C$6,000,000, after taking into account all expenses associated with the Proposed Transaction; and (ix) Mota completing a private placement of units to raise gross proceeds of not less than C$5,000,000 (the “Mota Financing“). The Proposed Transaction cannot be completed until these conditions are satisfied. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

The proposed Mota Financing will consist of units at a price of C$0.45 per unit, with each unit comprised of one Mota common share and one share purchase warrant of Mota. Each such warrant will be exercisable to purchase one common share of Mota at a price of C$0.60 for a period of two years. All securities to be issued in connection with the Mota Financing will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws. Mota anticipates paying finders fees to certain eligible parties who have introduced subscribers to the Mota Financing.

The board of directors of each of Mota, and Stillcanna, have unanimously approved the Letter of Intent. Further information about the Proposed Transaction will be included in subsequent press releases when available.

About Mota Ventures Corp.

Mota is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota.

About Stillcanna Inc.

Stillcanna is a Canadian early-stage life sciences company focused on the large-scale manufacturing of CBD in Europe using its proprietary intellectual property. Stillcanna has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly Biosciences LLC, a United Kingdom-based supplier of CBD. Stillcanna also recently completed the acquisition of Olimax NT SP.Z.O.O., a multi-generational hemp agricultural firm that is expected to increase market share in the European CBD industry.

On behalf of Mota Ventures Corp.

Ryan Hoggan
Chief Executive Officer

On behalf of Stillcanna Inc.

Jason Dussault

Chief Executive Officer

For more information visit

www.motaventuresco.com or contact:

Investor Relations

[email protected]
+1.604.423.4733

For more information visit www.stillcanna.com or contact:

Mauricio Inzunza
[email protected]

Mota Ventures $MOTA.ca Signs Letter of Intent for Merger with Stillcanna $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM at 6:10 PM on Wednesday, February 26th, 2020
http://www.smallcapepicenter.com/Mota%20Square%20Logo%20For%20Blog.jpg
  • Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts
  • Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe

VANCOUVER, BC / ACCESSWIRE / February 26, 2020 / Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF)(FRANKFURT:1WZGR) (“Mota“) and Stillcanna Inc. (STIL)(SCNNF)(A2PEWA) (“Stillcanna“) are pleased to announce that they have entered into a letter of intent (the “Letter of Intent“), dated effective February 25, 2020, pursuant to which Mota proposes to acquire all of the outstanding share capital of Stillcanna (the “Proposed Transaction“).

Strategic Merger

Mota is a globally-focused CBD product development and marketing company with established online retail brands in both the U.S. and Europe. Through its acquisition of First Class CBD, Mota has become a significant direct-to-consumer retail brand in the United States. In 2019, First Class CBD (then, a division of Unified Funding, LLC) realized approximately C$28.7 million in revenue with an EBITDA of approximately 12.5%.1 Mota’s successful e-commerce platform currently serves over 140,000 online customers and has generated over 400,000 leads in the United States. With the roll-out of First Class CBD’s proven e-marketing strategy throughout Europe, Mota believes that a merger with a high-quality CBD producer is of paramount importance in order to capture the large margins in the CBD-product supply chain.

Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts. Using proprietary extraction techniques and purpose-built equipment, Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe. Stillcanna’s Polish extraction facility, NEXUS, features industrial-scale centrifugal chromatography equipment that allows for the production of bulk THC-free CBD distillate as well as custom Cannabinoid profiles. In February 2020, Stillcanna’s Romanian extraction facility, ORIGIN, which operates pursuant to a joint venture between Stillcanna and Dragonfly Biosciences Ltd., received approval from the Ministry of Health and the Anti-Drug Agency to become the first government recognized extraction facility in the country. To date C$23,000,000 has been invested by Stillcanna in the cultivation and extraction operations, with current cash on hand in Stillcanna of approximately C$7,000,000.

Stillcanna’s CBD extracts are key to unlocking additional value in Mota’s retail offerings in Europe. Through Stillcanna, Mota hopes to guarantee the supply of high-quality CBD for its expanding product line in Europe, while the large production capacity of NEXUS and ORIGIN will allow Mota to be a key supplier of legal CBD products in Europe.

“We are very excited to pursue a transaction with Stillcanna. The merger of this large-scale, high-quality CBD producer will fit brilliantly with Mota’s strategic expansion plan to vertically integrate operations in Europe while increasing profit margins in product offerings. Product awareness and availability are still quite limited in Europe, which presents an opportunity for Mota to further establish its brands in a market that is expected to experience rapid growth in the near term. With the Stillcanna merger, we’re putting together a team that can create, market and sell consumer CBD products to European customers,” stated Ryan Hoggan, CEO of Mota.

“Combining a company that has established brands and direct-to-consumer sales channels with one that has proven CBD extraction expertise makes perfect sense to us,” commented Jason Dussault, CEO of Stillcanna. “The wholesale landscape for CBD has changed dramatically in the past year, and the creation of a seed-to-consumer CBD company in the growing European market creates a direct path to profitability. This merger completes the circle for Stillcanna, evolving from a seed to CBD concentrate company to a seed to retail sales company.”

Merger Details

Under the terms of the Proposed Transaction, Mota would acquire all of the outstanding share capital of Stillcanna by way of a statutory plan of arrangement under the Business Corporations Act of British Columbia Canada. Shareholders of Stillcanna (the “Stillcanna Shareholders“) would receive one common share of Mota for every 1.8 common shares of Stillcanna held at the time of exchange (the “Exchange Ratio“). Based on the current outstanding common share capital of Stillcanna, it is anticipated that Mota would issue approximately 61,597,082 Mota shares to complete the Proposed Transaction.

Upon completion of the Proposed Transaction: (i) all outstanding incentive stock options of Stillcanna will be exchanged for options to purchase Mota shares on the basis of the Exchange Ratio and will thereafter be subject to the incentive stock option plan of Mota; and (ii) all unexercised share purchase warrants of Stillcanna will be exchanged for warrants to purchase Mota shares on the basis of the Exchange Ratio and will expire in accordance with their current expiry dates.

Mota and Stillcanna are at arms-length. The Proposed Transaction does not constitute a reverse-takeover of Mota, nor is it expected to result in a change of control of Mota within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Upon completion of the Proposed Transaction, there will be no changes to the management or the board of directors of Mota and it is expected that members of management and the board of Stillcanna will continue to assist in relation to the management of Stillcanna’s business.

Completion of the Proposed Transaction remains subject to a number of conditions, including, but not limited to: (i) satisfactory completion of due diligence; (ii) negotiation of definitive, legally-binding documentation; (iii) receipt of any required regulatory approvals, including the court; (iv) the approval of the Stillcanna Shareholders; (v) receipt of a satisfactory fairness opinion in respect of the Proposed Transaction; (vi) Stillcanna having arranged to amend the terms of certain existing employment and consulting engagements; (vii) shareholders of Stillcanna holding at least 40,000,000 of the outstanding share capital of Stillcanna having agreed to the terms of a pooling arrangement restricting their ability to trade one-half of the Mota shares they receive for a period of six months following completion of the Proposed Transaction; (viii) Stillcanna having positive working capital of not less than C$6,000,000, after taking into account all expenses associated with the Proposed Transaction; and (ix) Mota completing a private placement of units to raise gross proceeds of not less than C$5,000,000 (the “Mota Financing“). The Proposed Transaction cannot be completed until these conditions are satisfied. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

The proposed Mota Financing will consist of units at a price of C$0.45 per unit, with each unit comprised of one Mota common share and one share purchase warrant of Mota. Each such warrant will be exercisable to purchase one common share of Mota at a price of C$0.60 for a period of two years. All securities to be issued in connection with the Mota Financing will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws. Mota anticipates paying finders fees to certain eligible parties who have introduced subscribers to the Mota Financing.

The board of directors of each of Mota, and Stillcanna, have unanimously approved the Letter of Intent. Further information about the Proposed Transaction will be included in subsequent press releases when available.

About Mota Ventures Corp.

Mota is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota.

About Stillcanna Inc.

Stillcanna is a Canadian early-stage life sciences company focused on the large-scale manufacturing of CBD in Europe using its proprietary intellectual property. Stillcanna has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly Biosciences LLC, a United Kingdom-based supplier of CBD. Stillcanna also recently completed the acquisition of Olimax NT SP.Z.O.O., a multi-generational hemp agricultural firm that is expected to increase market share in the European CBD industry.

On behalf of Mota Ventures Corp.

Ryan Hoggan
Chief Executive Officer

On behalf of Stillcanna Inc.

Jason Dussault

Chief Executive Officer

For more information visit

www.motaventuresco.com or contact:

Investor Relations

[email protected]
+1.604.423.4733

For more information visit www.stillcanna.com or contact:

Mauricio Inzunza
[email protected]